Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Geoffrey J. Lindeman, MBBS, PhD, on Venetoclax Plus Fulvestrant or Fulvestrant Alone: Clinical Implications of New Findings in Breast Cancer

Posted: Monday, June 21, 2021

Geoffrey J. Lindeman, MBBS, PhD, of Peter MacCallum Cancer Centre, discusses the VERONICA trial findings on treating women with advanced or metastatic breast cancer with venetoclax plus fulvestrant or fulvestrant alone as well as managing any related toxicities.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.